Lantheus (LNTH) stock tumbled 6.52% in pre-market trading on Wednesday following the release of its first-quarter 2025 financial results, which fell short of analysts' expectations. The disappointing earnings report has sparked concerns among investors about the company's near-term growth prospects.

The medical imaging and diagnostics company reported adjusted earnings per share (EPS) of $1.53 for Q1 2025, significantly below the $1.66 consensus estimate from IBES. Revenue for the quarter came in at $372.8 million, also missing the projected $379 million. These misses on both top and bottom lines appear to be the primary drivers behind the stock's pre-market decline.

Despite the underwhelming performance relative to expectations, Lantheus did report some positive figures. The company's GAAP EPS stood at $1.02 for the quarter, and it generated a robust free cash flow of $98.8 million. However, these metrics seem insufficient to offset investor disappointment with the overall results. As the market digests this financial update, all eyes will be on Lantheus' management for guidance on future performance and strategies to address the shortfall in the coming quarters.